Online inquiry

IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ9695MR)

This product GTTS-WQ9695MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KLRK1 gene. The antibody can be applied in Crohn's disease (CD) research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_007360.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	22914
UniProt ID	P26718

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9695MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ12052MR	IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MNRP1685A
GTTS-WQ2127MR	IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ALD-403
GTTS-WQ10061MR	IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	L19-IL-2
GTTS-WQ1455MR	IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ACD22-VCMMAE
GTTS-WQ12469MR	IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	NN-8226
GTTS-WQ8340MR	IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	hPAM4
GTTS-WQ5187MR	IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	CAT-354
GTTS-WQ5764MR	IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	CetuxiMab-GEX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST